About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

Agents that Target Disease Pathways >  Targeting apoptosis

or more precisely: inhibiting the inhibitors of apoptosis

Last update: 09/09/2015

Comment or Question? | In the News  | Clinical Trials | ABT 199

Apoptosis and necrosis are two major ways by which cells die. Apoptosis is the ordered disassembly of the cell from within. It's a natural mechanism by which cells "commit suicide" when they have outlived their purpose, become defective, or have aged. 

... The old or defective cells "take one for the team." That some cells die and other live on to replicate helps to achieve a balance in the body. What happens in a cancer cell is that some parts of the cell machinery that carry out, signal for, or authorize apoptosis no longer function ... because of damage to genes that produce proteins that regulate or carry out these functions.
 

So the search has been on to identify how cancer cells resist cell death and then to design a drug that inhibits this mechanism.  This class of drugs is sometimes called inhibitors of the inhibitors of apoptosis - agents that allows the "red KILL button" to be pressed.

Chances are you've seen a movie with apoptosis as part of the plot ... in almost any James Bond film.   A fortress containing classified information is rigged for destruction by the owners if the security of the building is compromised. The process requiring a series of commands, which are relayed from one authorized person to another. This to prevent a programmed self-destruction by a careless mistake or a rouge individual. The fail-safe system is carried out from within by specialists, and regulated by others.

... The trigger is not pulled until all the criteria is met: the security threat is real and it can't be corrected; the command has been given by authorized individuals and verified by others, and the actions carried out by specialized personnel.  The security breach starts a chain of events (a cascade); each player communicating to the other until the big red button is pushed and the building destroyed; the sensitive information within it evaporating.

Similarly, our cells are rigged for self destruction. Many chemotherapy treatments are designed to exploit apoptosis ... by causing sufficient damage to the cells that force the issue, magnifying the urgency to self-destruct. Waking up the components in the cell that authorize apoptosis, such as the P53 gene.

Imagine that a key protein within the cell is overactive and is giving a STOP order. Then imagine a small molecule drug that fits the shape of this protein, stopping the STOP order.

See for a video explanation of apoptosis by Cancerquest.org:


Agents targeting apoptosis in clinical phase testing   

Find for Class of therapy BCL-2 binding agents Epigenetic agents
PubMed Query of
Inihbitors of Apoptosis
ABT-199
Find trials 
Reports

ASCO report
See Epigenetic Therapy - HDAC inhibitoros
  Study of interest: not yet recruiting
ABT-199 + Rituxan Versus Bendamustine + Rituxan for Relapsed or Resistant CLL http://1.usa.gov/J0zsdl
 
 


In the News

* Onc Live 2013:
Dr. Seymour on the Efficacy of ABT-199 in High-Risk CLL http://bit.ly/1d6ZOnf

 


ABT 199

ABT-199 (venetoclax), a potent and selective BCL-2 inhibitor
 

Resources

bullet
Background and video on Selective BCL-2 Inhibitor (venetoclax) | BioOncology http://bit.ly/1O122KO 
bullet
Video interview: Dr. John Seymour on the Efficacy of ABT-199 in High-Risk CLL -  
bullet
ABT-199, a potent and selective BCL-2 inhibitor, ach... [Nat Med. 2013] - PubMed - NCBI http://1.usa.gov/1g3a6qJ

 

 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.